✦ LIBER ✦

A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study

✍ Scribed by Shimada, Noritomo; Tsubota, Akihito; Atsukawa, Masanori; Abe, Hiroshi; Ide, Tatsuya; Takaguchi, Koichi; Chuganji, Yoshimichi; Toyoda, Hidenori; Yoshizawa, Kai; Ika, Makiko; Sato, Yoshiyuki; Kato, Keizo; Kumada, Takashi; Sakamoto, Choitsu; Aizawa, Yoshio; Sata, Michio

Book ID: 121666636
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 600 KB
Volume: 44
Category: Article
ISSN: 1386-6346
DOI: 10.1111/hepr.12323

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline factors and very early viral re

Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study

✍ Shimada, Noritomo; Toyoda, Hidenori; Tsubota, Akihito; Ide, Tatsuya; Takaguchi, 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 295 KB

Baseline factors and early viral respons

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study

✍ Toyoda, Hidenori; Kumada, Takashi; Shimada, Noritomo; Takaguchi, Koichi; Ide, Ta 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Potent induction therapy with interferon

Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

✍ Shotaro Enomoto; Hideyuki Tamai; Masashi Oka; Naoki Shingaki; Tatsuya Shiraki; M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

505 The influence of cumulative exposure

505 The influence of cumulative exposure to combination peginterferon alfa-2A (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C

✍ K.R. Reddy; M.W. Fried; M.L. Shiffman; S.J. Hadziyannis; H. Sette; T.R. Morgan; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 49 KB

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

✍ Manns, M.; Muir, A.; Adda, N.; Jacobson, I.; Afdhal, N.; Heathcote, J.; Zeuzem, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 91 KB

A matched case-controlled study of 48 an

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther